arrow_back Back to App

Strengthening Antibiotic Resistance Fight: New Strategies and Oversight

This act aims to strengthen the U.S. government's efforts in combating growing antibiotic resistance. It means better monitoring, faster threat detection, and the development of new drugs, directly leading to more effective infection treatment and greater public health safety for citizens.
Key points
Enhanced coordination of federal efforts to combat antibiotic resistance, including public task force meetings.
Increased surveillance of antibiotic use and bacterial resistance, with public data availability.
Establishment of regional laboratories to detect and monitor antibiotic resistance nationwide.
Support for research into new antibiotics and treatment methods through a clinical trials network.
Development of regional programs to prevent the spread of resistant bacteria in healthcare settings.
article Official text account_balance Process page
Expired
Citizen Poll
No votes cast
Additional Information
Print number: 117_S_3291
Sponsor: Sen. Brown, Sherrod [D-OH]
Process start date: 2021-12-01
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

STAAR Act

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 117_S_3291.

Which chamber initiated this legislation?

This legislation was initiated in the Senate.

When did the legislative process begin?

The process officially started on 2021-12-01.

What are the main provisions?

Key points include:

  • Enhanced coordination of federal efforts to combat antibiotic resistance, including public task force meetings.
  • Increased surveillance of antibiotic use and bacterial resistance, with public data availability.
  • Establishment of regional laboratories to detect and monitor antibiotic resistance nationwide.
  • Support for research into new antibiotics and treatment methods through a clinical trials network.
  • Development of regional programs to prevent the spread of resistant bacteria in healthcare settings.
What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Sen. Brown, Sherrod [D-OH].

What is the latest detailed status?

The latest detailed status is: Introduced in Senate

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-29.

CATEGORIES

Health